216 related articles for article (PubMed ID: 28238427)
1. Development of a non-radiolabeled glucosyltransferase activity assay for C. difficile toxin A and B using ultra performance liquid chromatography.
Loughney JW; Lancaster C; Price CE; Hoang VM; Ha S; Rustandi RR
J Chromatogr A; 2017 May; 1498():169-175. PubMed ID: 28238427
[TBL] [Abstract][Full Text] [Related]
2. High temporal resolution of glucosyltransferase dependent and independent effects of Clostridium difficile toxins across multiple cell types.
D'Auria KM; Bloom MJ; Reyes Y; Gray MC; van Opstal EJ; Papin JA; Hewlett EL
BMC Microbiol; 2015 Feb; 15(1):7. PubMed ID: 25648517
[TBL] [Abstract][Full Text] [Related]
3. Structural determinants of Clostridium difficile toxin A glucosyltransferase activity.
Pruitt RN; Chumbler NM; Rutherford SA; Farrow MA; Friedman DB; Spiller B; Lacy DB
J Biol Chem; 2012 Mar; 287(11):8013-20. PubMed ID: 22267739
[TBL] [Abstract][Full Text] [Related]
4. Substrate specificity of clostridial glucosylating toxins and their function on colonocytes analyzed by proteomics techniques.
Zeiser J; Gerhard R; Just I; Pich A
J Proteome Res; 2013 Apr; 12(4):1604-18. PubMed ID: 23387933
[TBL] [Abstract][Full Text] [Related]
5. Structure of the glucosyltransferase domain of TcdA in complex with RhoA provides insights into substrate recognition.
Chen B; Liu Z; Perry K; Jin R
Sci Rep; 2022 May; 12(1):9028. PubMed ID: 35637242
[TBL] [Abstract][Full Text] [Related]
6. The structure of Clostridium difficile toxin A glucosyltransferase domain bound to Mn2+ and UDP provides insights into glucosyltransferase activity and product release.
D'Urzo N; Malito E; Biancucci M; Bottomley MJ; Maione D; Scarselli M; Martinelli M
FEBS J; 2012 Sep; 279(17):3085-97. PubMed ID: 22747490
[TBL] [Abstract][Full Text] [Related]
7. Clostridium difficile toxins: more than mere inhibitors of Rho proteins.
Genth H; Dreger SC; Huelsenbeck J; Just I
Int J Biochem Cell Biol; 2008; 40(4):592-7. PubMed ID: 18289919
[TBL] [Abstract][Full Text] [Related]
8. Autoproteolytic cleavage mediates cytotoxicity of Clostridium difficile toxin A.
Kreimeyer I; Euler F; Marckscheffel A; Tatge H; Pich A; Olling A; Schwarz J; Just I; Gerhard R
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):253-62. PubMed ID: 21046073
[TBL] [Abstract][Full Text] [Related]
9. Clostridium difficile Toxin Biology.
Aktories K; Schwan C; Jank T
Annu Rev Microbiol; 2017 Sep; 71():281-307. PubMed ID: 28657883
[TBL] [Abstract][Full Text] [Related]
10. Release of TcdA and TcdB from Clostridium difficile cdi 630 is not affected by functional inactivation of the tcdE gene.
Olling A; Seehase S; Minton NP; Tatge H; Schröter S; Kohlscheen S; Pich A; Just I; Gerhard R
Microb Pathog; 2012 Jan; 52(1):92-100. PubMed ID: 22107906
[TBL] [Abstract][Full Text] [Related]
11. Lectin Activity of the TcdA and TcdB Toxins of Clostridium difficile.
Hartley-Tassell LE; Awad MM; Seib KL; Scarselli M; Savino S; Tiralongo J; Lyras D; Day CJ; Jennings MP
Infect Immun; 2019 Mar; 87(3):. PubMed ID: 30530621
[No Abstract] [Full Text] [Related]
12. Harnessing the glucosyltransferase activities of Clostridium difficile for functional studies of toxins A and B.
Darkoh C; Kaplan HB; Dupont HL
J Clin Microbiol; 2011 Aug; 49(8):2933-41. PubMed ID: 21653766
[TBL] [Abstract][Full Text] [Related]
13. Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile.
Dingle T; Wee S; Mulvey GL; Greco A; Kitova EN; Sun J; Lin S; Klassen JS; Palcic MM; Ng KK; Armstrong GD
Glycobiology; 2008 Sep; 18(9):698-706. PubMed ID: 18509107
[TBL] [Abstract][Full Text] [Related]
14. Use of a neutralizing antibody helps identify structural features critical for binding of
Kroh HK; Chandrasekaran R; Rosenthal K; Woods R; Jin X; Ohi MD; Nyborg AC; Rainey GJ; Warrener P; Spiller BW; Lacy DB
J Biol Chem; 2017 Sep; 292(35):14401-14412. PubMed ID: 28705932
[No Abstract] [Full Text] [Related]
15. Masking autoprocessing of Clostridium difficile toxin A by the C-terminus combined repetitive oligo peptides.
Zhang Y; Hamza T; Gao S; Feng H
Biochem Biophys Res Commun; 2015 Apr; 459(2):259-263. PubMed ID: 25725153
[TBL] [Abstract][Full Text] [Related]
16. TcdB of
Stieglitz F; Gerhard R; Hönig R; Giehl K; Pich A
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457076
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning, overexpression in Escherichia coli, and purification of 6x his-tagged C-terminal domain of Clostridium difficile toxins A and B.
Letourneur O; Ottone S; Delauzun V; Bastide MC; Foussadier A
Protein Expr Purif; 2003 Oct; 31(2):276-85. PubMed ID: 14550648
[TBL] [Abstract][Full Text] [Related]
18. Clostridium difficile toxin glucosyltransferase domains in complex with a non-hydrolyzable UDP-glucose analogue.
Alvin JW; Lacy DB
J Struct Biol; 2017 Jun; 198(3):203-209. PubMed ID: 28433497
[TBL] [Abstract][Full Text] [Related]
19. Development of a dose assay for a Clostridium difficile vaccine using a tandem ion exchange high performance liquid chromatography method.
Wang F; Ha S; Rustandi RR
J Chromatogr A; 2017 May; 1498():163-168. PubMed ID: 28366569
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Clostridium difficile Infection with a Small-Molecule Inhibitor of Toxin UDP-Glucose Hydrolysis Activity.
Stroke IL; Letourneau JJ; Miller TE; Xu Y; Pechik I; Savoly DR; Ma L; Sturzenbecker LJ; Sabalski J; Stein PD; Webb ML; Hilbert DW
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483125
[No Abstract] [Full Text] [Related]
[Next] [New Search]
